These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10414753)

  • 1. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
    Kolvenbag GJ; Furr BJ
    Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

  • 3. Casodex: preclinical studies and controversies.
    Furr BJ
    Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
    [No Abstract]   [Full Text] [Related]  

  • 4. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated potency of Casodex: a problematic design.
    Labrie F; Simard J; Singh SM; Candas B
    Urology; 1997 Aug; 50(2):309-13. PubMed ID: 9255312
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 7. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
    Sarosdy MF
    Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicalutamide versus flutamide in combination therapy.
    Labrie F; Candas B
    Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
    [No Abstract]   [Full Text] [Related]  

  • 9. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bicalutamide dosages used in the treatment of prostate cancer.
    Kolvenbag GJ; Nash A
    Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR; Cockshott ID; Furr BJ
    Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New indication sought for bicalutamide.
    Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
    Palmberg C; Kylmala T; Tammela T
    Br J Urol; 1997 May; 79(5):808-9. PubMed ID: 9158528
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiandrogen monotherapy in the management of advanced prostate cancer.
    Kaisary AV
    Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995.
    Urology; 1996 Jan; 47(1A Suppl):1-96. PubMed ID: 8560672
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide ('Casodex') development: from theory to therapy.
    Kolvenbag GJ; Furr BJ
    Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
    [No Abstract]   [Full Text] [Related]  

  • 20. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.